Send to:

Choose Destination
See comment in PubMed Commons below
Hematol Oncol Clin North Am. 1994 Oct;8(5):1011-20.

Clinical application of recombinant erythropoietin in the perioperative period.

Author information

  • 1Department of Medicine, Washington University School of Medicine, St. Louis, Missouri.


Recombinant human erythropoietin (EPO) therapy as an alternative to allogenic blood transfusion has been studied extensively in the perisurgical period. The potential benefits of EPO in this setting are twofold; EPO enhances autologous blood collection in advance of elective surgery and stimulates erythropoiesis perioperatively. Clinical evidence of the role of EPO therapy in these settings to minimize allogenic blood exposure is presented.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk